Vastarel MR

Vastarel MR

trimetazidine

Manufacturer:

Servier

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Trimetazidine diHCl
Indications/Uses
Add-on therapy for symptomatic treatment in adults w/ stable angina pectoris who are inadequately controlled by or intolerant to 1st-line antianginal therapy.
Dosage/Direction for Use
1 tab bd. Moderate renal impairment (CrCl 30-60 mL/min) 1 tab in the morning.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Parkinson's disease, parkinsonian symptoms, tremors, restless leg syndrome & other related movement disorders. Severe renal impairment (CrCl <30 mL/min).
Special Precautions
Not a curative treatment for angina attacks or as initial treatment for unstable angina, MI, pre-hospital phase or during 1st days of hospitalisation. Discontinue use if movement disorders eg, parkinsonian symptoms, restless leg syndrome, tremors, gait instability occur. Falls related to gait instability or hypotension. Positive result in anti-doping tests. May affect ability to drive & use machines. Moderate renal impairment. Avoid use during pregnancy. Not to be used during lactation. Childn <18 yr. Elderly >75 yr.
Adverse Reactions
Dizziness, headache; abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; rash, pruritus, urticaria; asthenia.
MIMS Class
Anti-Anginal Drugs
ATC Classification
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.
Presentation/Packing
Form
Vastarel MR MR-FC tab 35 mg
Packing/Price
60's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in